[MDT] Medtronic: Q2 Fiscal 2027 Earnings Preview on Pulsed Field Ablation After MiniMed

Medtronic is one of the world's largest medical device makers, selling implants, catheters, surgical instruments and monitoring equipment across cardiovascular, neuroscience and medical surgical markets to hospitals and surgery centers in more than 150 countries through direct sales representatives and distributors[1]. Ahead of Medtronic's Q2 fiscal 2027 earnings, the company is scheduled to report on 2026-11-24 for the Second quarter of fiscal year 2027 (three months ended around October 30, 2026)[2], its first quarterly report since it completed the split-off of the MiniMed diabetes business on October 15[3]. In the latest disclosed period, the first quarter of fiscal 2027 (April 25 to July 31, 2026, a 14-week quarter), revenue was $9.756 billion[4], reported and organic growth were both 13.7%, the extra week added roughly $570 million of revenue, and diluted EPS was $1.45 on a non-GAAP basis and $1.14 under GAAP[5]. On the first-quarter call, management guided to about 6% organic revenue growth and non-GAAP EPS of $1.32 to $1.34 for the second quarter[6], and on the same day it raised fiscal 2027 guidance to 7.25% to 7.75% organic growth and non-GAAP EPS of $5.94 to $6.00[5]; the analyst consensus compiled in the earnings calendar on November 10 stands at second-quarter EPS of $1.332 and revenue of about $9.497 billion, a revenue figure that roughly equals the prior-year quarter's actual $8.961 billion plus 6% and may therefore still assume a full quarter of diabetes revenue[2].

Three things matter most in this report. The first is whether pulsed field ablation (PFA) can still carry the heart-rhythm business without the extra week: first-quarter Electrophysiology Therapies (EPT) revenue was $2.218 billion, up 30%[4], and Cardiac Ablation Solutions (CAS) grew 88%[5], but both figures include 14 weeks, so second-quarter growth on a 13-week basis will be the first clean reading of PFA's underlying momentum. The second is whether underlying growth and EPS land inside guidance after the separation: the second quarter is the first without both the extra week and MiniMed, and whether the company delivers about 6% organic growth and EPS of $1.32 to $1.34[6], and how it resets full-year guidance, will set the comparison base for the rest of fiscal 2027. The third is why margins did not expand with growth: revenue rose 13.7% in the first quarter, yet the non-GAAP gross margin of 65.2% and operating margin of 23.7% were each only 10 basis points higher than a year earlier[6], and the Medical Surgical segment margin fell from 23.7% to 21.3%[7], so second-quarter margins will show whether the improvement was a short-lived benefit of the extra week and tariff refunds or the start of a product-mix drag.

Company Background and Business Structure

Medtronic is a diversified device company domiciled in Ireland with its operating roots in the United States. Founded in Minneapolis in 1949, it moved its legal domicile to Ireland after acquiring Covidien in 2015 and is headquartered in Galway; Geoff Martha is chairman and chief executive officer, and Thierry Piéton is chief financial officer[8]. The fiscal year ends on the last Friday of April, and fiscal 2027 is a 53-week year with the extra week falling in the first fiscal month of the first quarter[9], which naturally inflates first-quarter year-over-year comparisons.

Cardiovascular is the largest segment, and from fiscal 2027 it is reported as four divisions. In fiscal 2026, Cardiovascular revenue was $13.976 billion, up 12%; Neuroscience was $10.287 billion, up 4%; and Medical Surgical was $8.815 billion, up 5%, for combined reportable segment sales of $33.079 billion[10]. Starting in the first quarter of fiscal 2027, Cardiovascular is split into Electrophysiology Therapies (EPT, covering pacemakers, defibrillators and other cardiac rhythm devices plus cardiac ablation), Interventional Cardiology Therapies (ICT, covering transcatheter aortic valves or TAVR, coronary devices and Symplicity renal denervation), CardioVascular Surgery (CVS) and Peripheral Vascular Health (PVH), with first-quarter revenue of $2.218 billion, $894 million, $477 million and $338 million respectively[4].

Neuroscience and Medical Surgical each consist of several established businesses and were reinforced through acquisitions in 2026. Within fiscal 2026 Neuroscience, Cranial and Spinal Technologies (implants, Stealth navigation and robotics) generated $5.222 billion, Specialty Therapies (neurovascular, ear-nose-throat and pelvic health) $2.997 billion and Neuromodulation (spinal cord and deep brain stimulation) $2.068 billion; within Medical Surgical, Surgical and Endoscopy (staplers, LigaSure energy devices, hernia repair and the Hugo surgical robot) generated $6.764 billion and Acute Care and Monitoring $2.051 billion[10]. In June and July 2026, the company acquired neurovascular guidewire maker Scientia Vascular for $681 million and peripheral nerve stimulation company SPR Therapeutics for $654 million[9].

The diabetes business has fully left Medtronic through a two-step IPO and share exchange. The diabetes business (insulin pumps and continuous glucose monitoring) generated fiscal 2026 revenue of $3.112 billion, up 13%, and stopped being a reportable segment from the fourth quarter[10]; MiniMed completed its IPO at $20 per share on March 9, 2026, raising net proceeds of $538 million, while Medtronic kept about 90.03% of the shares and agreed to provide transition services generally for no more than 24 months[11]. In October, Medtronic put all of its remaining 252,813,348 MiniMed shares into an exchange offer that was 5.4 times subscribed, and it announced the completed separation on October 15[3].

The customer base is highly fragmented, and revenue is split roughly evenly between the United States and international markets. Products are sold mainly by direct sales representatives and third-party distributors to hospitals, ambulatory surgery centers and physician offices, with pricing usually set in supply contracts negotiated with group purchasing organizations (GPOs) and integrated delivery networks (IDNs); part of revenue comes from consignment inventory held at hospitals, and no single customer accounts for more than 10% of total net sales[1]. Of fiscal 2026 reportable segment revenue, $17.088 billion came from the United States and $15.991 billion from international markets, while about 70% of diabetes revenue came from outside the United States[8].

Financial History and Current Position

Medtronic's revenue growth accelerated clearly in fiscal 2026 after two slower years. According to the 10-K, revenue rose from $32.364 billion in fiscal 2024 to $33.537 billion in fiscal 2025 and $36.364 billion in fiscal 2026[8], an 8% increase in fiscal 2026, with the three reportable segments together up 8% and diabetes up 13%[10]. Fiscal 2026 GAAP net income attributable to Medtronic was $4.800 billion, or $3.73 per diluted share[8]; reportable segment operating profit totaled $8.862 billion, made up of $3.672 billion from Cardiovascular, $3.062 billion from Neuroscience and $2.128 billion from Medical Surgical, and after net interest of $715 million and intangible amortization of $1.772 billion, among other items, income before taxes was $6.136 billion[12].

Annual cash flow is steady, but tariffs have started to eat into gross profit. Fiscal 2026 operating cash flow was $7.330 billion (versus $7.044 billion in fiscal 2025 and $6.787 billion in fiscal 2024), capital expenditure was $1.904 billion and free cash flow was about $5.426 billion; the company paid $3.639 billion in dividends, repurchased $1.035 billion of shares (down from $3.235 billion in fiscal 2025) and spent $406 million on acquisitions[13]. In the same year, cost of products sold rose from $11.6 billion to $12.7 billion and increased as a share of sales, mainly because of $185 million of higher tariffs and duties on imported goods and $84 million of asset write-offs, and the company said it anticipates additional tariff-related costs[14].

The first-quarter fiscal 2027 income statement beat guidance across the board but included the extra week. First-quarter revenue was $9.756 billion against $8.578 billion a year earlier[4]; the company said revenue came in roughly 200 basis points above the guidance midpoint, with GAAP EPS of $1.14, non-GAAP EPS of $1.45 and about $570 million of revenue from the extra week[5]. In the same quarter, the non-GAAP gross margin was 65.2% and the GAAP gross margin was 65.0%, while the non-GAAP operating margin was 23.7%, with both non-GAAP margins 10 basis points higher than a year earlier[6].

First-quarter cash generation improved sharply, and the balance sheet stayed stable ahead of the separation. Operating cash flow was $1.793 billion and capital expenditure $503 million, giving free cash flow of $1.290 billion, more than double the prior-year $584 million, while acquisitions used $1.162 billion of cash[15]. At the end of July, the company held $1.691 billion of cash and $7.128 billion of investments, or $8.819 billion in total, against current debt of $2.536 billion and long-term debt of $25.617 billion, or $28.153 billion in total, leaving net debt of about $19.3 billion with roughly 1.280 billion ordinary shares outstanding[16]; the October exchange offer swapped MiniMed stock for Medtronic shares, involving no cash but reducing the share count[3].

Operating Model

Medtronic's revenue can be broken down into procedure volume times device price, plus sales of capital equipment such as navigation systems, ablation consoles and surgical robots. Each segment's revenue depends mainly on procedure volume and new-product penetration, for example PFA catheters, Symplicity renal denervation, spinal navigation and pelvic stimulation; capital equipment is installed first and catheters and disposables are reordered over the following quarters, so installations lift revenue before disposables do, while disposables determine how durable growth is[17]. Fiscal 2026 reportable segment revenue was $33.079 billion[10], and the extra week added about $570 million in the first quarter[5], an effect that disappears when the second quarter returns to 13 weeks.

Segment operating profit equals revenue minus cost of products sold, R&D and SG&A, and product mix is the variable margins are most sensitive to. In fiscal 2026, segment margins were 26.3% for Cardiovascular, 29.8% for Neuroscience and 24.1% for Medical Surgical[12]; in the first quarter of fiscal 2027, Cardiovascular rose to 26.3% (from 25.2%), Neuroscience was 29.6% and Medical Surgical fell to 21.3% (from 23.7%)[7]. First-quarter cost of products sold was flat as a share of sales because favorable pricing and cost-down initiatives were offset by unfavorable mix, and tariffs had no material year-over-year impact once refunds were included[18]; a higher share of high-margin catheters and spinal disposables lifts gross margin, while a higher share of lower-margin consoles and robots pulls it down, usually within the same quarter.

The cash model is operating cash flow minus capital expenditure, with the result allocated to dividends, buybacks and acquisitions. Fiscal 2026 free cash flow of about $5.426 billion went mainly to $3.639 billion of dividends[13]; first-quarter free cash flow was $1.290 billion, while acquisitions used $1.162 billion[15]. Because MiniMed was split off through a share exchange, it brought in no cash, but it reduces the share count, which lowers future total dividends and lifts EPS[3].

The direction of the separation's financial effect is clear, but its size will only be confirmed by second-quarter disclosures. The diabetes business generated fiscal 2026 revenue of $3.112 billion, about 8.6% of the total, with a higher international share than the rest of the company[10]; removing it lowers the revenue base and takes out a lower-margin business, while the exchange retired about 55 million shares, roughly 4.3% of the share count, lifting EPS and partly offsetting the lost MiniMed profit[3]. The other side of this transmission is that shared-service costs previously allocated to diabetes remain with Medtronic until the transition services agreement runs out[11].

Industry and Competitive Position

Medtronic ranks first or second in several device markets, but it faces a different strong rival in each one. In cardiac rhythm management it competes with Abbott and Boston Scientific, in spine with Stryker and Globus, in surgical energy devices and staplers with J&J, and neuromodulation is also a traditional strength. Its breadth means it does not depend on any single product, but it also means its competitive position has to be judged market by market.

Cardiac ablation is the fastest-growing market, and Medtronic is a challenger in it rather than the first mover. Ablation is shifting from cryo and radiofrequency energy to pulsed field ablation; Boston Scientific's Farapulse moved earliest, and Medtronic is catching up with PulseSelect, the Affera mapping and navigation system and the dual-energy Sphere-9 catheter, while the Sphere-360 single-shot catheter received CE Mark in January 2026 and Affera with Sphere-9 received an expanded CE Mark indication for ventricular arrhythmias in August 2026[17]. In fiscal 2026, Cardiac Rhythm and Heart Failure grew 17%, driven by strong growth in the pulsed ablation portfolio partly offset by declines in cryoablation[19]; figures cited by TIKR show CAS grew 88% worldwide and 139% in the United States in the first quarter, with trailing 12-month revenue above $2 billion[20].

In structural heart and surgical robotics, Medtronic's position is weaker and the comparison has more limits. In TAVR it competes with Edwards and Abbott, and first-quarter ICT revenue grew 7%, driven by TAVR, Symplicity renal denervation, guide catheters and balloons[17]; Intuitive Surgical dominates surgical robotics, Medtronic's Hugo was cleared in the United States for urology in 2026, and on its first-quarter results day the company announced a strategic partnership with Cornerstone Robotics[5], which TIKR describes as a $700 million investment plus a distribution agreement for select markets outside the United States[20]. The available material is limited because sub-businesses such as CAS and cardiac rhythm management disclose only growth rates, and the fiscal 2027 cardiovascular divisions cannot be compared directly with the older 10-K structure[4].

Core Debates

Without the extra week, can Medtronic's pulsed field ablation keep its heart-rhythm business growing above 20%?

This question matters because PFA has become Medtronic's main source of growth. First-quarter Electrophysiology Therapies revenue was $2.218 billion, 22.7% of group revenue, and it contributed $506 million of the Cardiovascular segment's $642 million revenue increase[4]. Cardiovascular generated fiscal 2026 operating profit of $3.672 billion, the largest of the three segments[12], so PFA growth and catheter reorders determine whether Medtronic can keep growing faster than the industry after separating diabetes.

Current evidence shows PFA's mix effect is starting to improve profit, but the growth rate includes one-off elements. The 10-Q attributes EPT's 30% growth to the pulsed field ablation portfolio and to pacing and defibrillation[17], and the results release gives 88% growth for cardiac ablation and 15% for cardiac rhythm management, all including 14 weeks[5]. The Cardiovascular segment margin rose from 25.2% to 26.3% in the first quarter[7], an early sign that a rising catheter share is improving mix; the numeric baseline is EPT revenue of $2.218 billion against $1.712 billion a year earlier, CAS growth of 88% and a Cardiovascular segment margin of 26.3% ($1.033 billion divided by $3.927 billion).

The path from growth to profit depends on whether installations turn into catheter reorders. Navigation console installations and physician training first lift PFA procedure volume per center, which then drives sales of single-use catheters such as Sphere-9, PulseSelect and, outside the United States, Sphere-360, and with them EPT revenue; a rising catheter share lowers the segment's cost-of-sales ratio and lifts segment margin within the quarter[7]. The alternative reading is that first-quarter growth partly reflected the extra week, concentrated console installations and self-substitution from cryoablation, so if installations slow or Boston Scientific and J&J cut prices, catheter reorder growth could fall quickly, and a heavy console mix would also weigh on segment margin[19].

Second-quarter data can test these two readings, though a single quarter will not settle the question. The points to watch are whether EPT revenue grows at least 20% year over year, whether CAS growth stays above 60% and the company keeps reporting US share gains, and whether the Cardiovascular segment operating margin holds at or above the first quarter's 26.3%[7]. If EPT growth falls below 20%, CAS growth below 50%, or the Cardiovascular margin drops below the prior-year level, growth would look more dependent on low-margin console installations, weakening the current understanding of PFA momentum.

After the MiniMed split-off, can Medtronic hold roughly 6% organic growth and in-range EPS in a normal 13-week quarter?

The second quarter matters because it will be the first without both the extra week and MiniMed. About $570 million of the first quarter's 13.7% revenue growth came from the extra week[5], leaving growth of roughly 7% without it; the share exchange completed on October 15 removes a diabetes business that generated $843 million of first-quarter revenue[4] and retires about 55 million shares[3]. Second-quarter growth and EPS will therefore set the comparison base for the rest of fiscal 2027.

Current evidence shows all three segments accelerating, but the acceleration mixes in the extra week and acquisitions. First-quarter organic growth was 18.9% in Cardiovascular, 9.3% in Neuroscience and 10.2% in Medical Surgical[5]; on a reported basis Neuroscience revenue was $2.678 billion against $2.427 billion and Medical Surgical $2.279 billion against $2.073 billion, both up about 10%[4], and Neuroscience also absorbed the Scientia Vascular and SPR Therapeutics acquisitions, worth about $1.3 billion combined[9]. Management guided to about 6% organic growth and EPS of $1.32 to $1.34 for the second quarter[6], and the consensus compiled in the earnings calendar is EPS of $1.332[2]; full-year guidance was raised in September to 7.25% to 7.75% organic growth and EPS of $5.94 to $6.00[5], but when first issued in June it assumed a full year of consolidated diabetes results, so it needs to be reset after the separation.

The separation's effect on EPS depends on the gap between the lower share count and the lost profit. Procedure volume and new-product penetration (PFA, Symplicity renal denervation, Altaviva pelvic stimulation and spinal navigation) drive organic revenue and operating profit in the three segments; deconsolidating MiniMed cuts revenue by about 8.6% and removes a lower-margin business, while retiring shares in the exchange reduces the weighted share count by about 4.3%, lifting EPS and partly offsetting the lost MiniMed profit[3]. The alternative reading is that the extra week, acquisitions and an easy base made the first quarter look strong and that underlying 13-week growth is only 5% to 6%; if post-separation guidance lowers the EPS range, it would show that the smaller share count does not make up for MiniMed's profit and the stranded costs left after the separation[11].

The answer will emerge from second-quarter results and the guidance reset that follows. The points to watch are whether second-quarter organic growth reaches the roughly 6% guidance, whether non-GAAP EPS lands in or above the $1.32 to $1.34 range, and whether the low end of reset full-year EPS guidance stays at or above $5.94[6]. If organic growth comes in below 5.5%, EPS below $1.32, or the low end of the reset EPS range below $5.94, the current understanding of post-separation underlying growth would be weakened.

With growth accelerating, why did Medtronic's margins improve by only 10 basis points?

Whether margins expand determines the quality of EPS growth after the separation. In fiscal 2026, tariffs and import duties added $185 million to cost of products sold, which rose as a share of sales[14]; in the first quarter of fiscal 2027 revenue grew 13.7%, yet the non-GAAP gross and operating margins each rose by only 10 basis points[6], and the Medical Surgical segment margin fell 2.4 percentage points[7]. Margins barely moving in a quarter of accelerating revenue suggests something is offsetting the benefit of scale.

Current evidence points to product mix rather than tariffs themselves. The 10-Q says first-quarter cost of products sold was flat as a share of sales because favorable pricing and cost-down initiatives were offset by unfavorable mix, and that tariffs had no material year-over-year impact once refunds were included[18]; the Cardiovascular margin rose 1.1 percentage points and Neuroscience also improved, but Medical Surgical operating profit fell from $494 million to $485 million and its margin from 23.7% to 21.3%[7]. The baseline also includes a non-GAAP gross margin of 65.2%, a GAAP gross margin of 65.0%, a non-GAAP operating margin of 23.7% and GAAP operating income of $1.764 billion (18.1%)[6], as well as first-quarter free cash flow of $1.290 billion against $584 million a year earlier, partly helped by the extra week[15].

Margin transmission is shaped by three forces at once: cost, tariffs and mix. Pricing, manufacturing-network consolidation and product-line simplification lower unit costs, tariffs and import duties raise cost of products sold, a higher share of high-margin catheters and spinal disposables lifts gross margin, and a higher share of lower-margin navigation consoles and surgical robots pulls it down; only after revenue growth spreads SG&A does the effect reach operating margin, and from there operating cash flow and free cash flow[18]. The alternative reading is that the slight gross-margin improvement came mainly from the extra week's scale and tariff refunds, and that the Medical Surgical margin decline reflects spending on the Hugo robot and the Cornerstone partnership, which would keep weighing on group margins in the second quarter[20].

Second-quarter margins can separate one-off factors from structural ones. The points to watch are whether the non-GAAP gross margin returns above 65.5%, whether the Medical Surgical segment margin stops falling and recovers above 22%, and whether first-half free cash flow exceeds the prior-year level[15]. If the non-GAAP gross margin drops below 65.0% or the non-GAAP operating margin falls below 23.0%, the mix drag would be persisting in a normal quarter, weakening the current understanding of margin improvement.

Risks and Falsifiers

Product quality and regulatory risk would hit the new growth platforms directly. Device recalls, FDA warning letters or delayed approvals would all affect sales, and the US approval timing for more Hugo indications and for Sphere-360 remains uncertain; the new growth platforms sit in Cardiovascular, with first-quarter revenue of $3.927 billion, and Medical Surgical, with $2.279 billion[4], and a large recall typically brings hundreds of millions of dollars of lost revenue and remediation costs. If the second quarter discloses no new major recall and Sphere-360 or new Hugo indications are approved on schedule, the threat this risk poses to the current understanding would recede[17].

PFA competition and pricing risk would affect both revenue and the Cardiovascular margin. Boston Scientific, J&J and other rivals could speed up installations and cut prices, slowing Medtronic's share gains and pressuring catheter prices; based on first-quarter EPT revenue of $2.218 billion, a slowdown from 30% to 15% growth would mean roughly $300 million less revenue per quarter[4] and would weigh on the Cardiovascular segment's 26.3% margin[7]. If second-quarter CAS growth is at least 60% and the Cardiovascular segment margin is at least 26.3%, this risk has not materialized[5].

Stranded costs after the separation could absorb the EPS lift from the lower share count. Once MiniMed leaves, shared-service and IT costs previously allocated to diabetes remain with Medtronic, and the transition services agreement generally runs for up to about 24 months[11]; diabetes generated fiscal 2026 revenue of $3.112 billion[10], and if shared costs are not cut in step, they would offset the EPS lift from a roughly 4.3% lower share count[3]. If the non-GAAP operating margin in the second quarter and in reset guidance holds at or above the first quarter's 23.7%, this concern would be falsified[5].

Tariff policy remains unsettled and is the most direct external pressure on gross margin. US tariffs on imported medical devices and components added $185 million of cost in fiscal 2026, and the 10-K flagged additional tariff costs ahead[14]; with first-quarter cost of products sold of about $3.4 billion and quarterly revenue of about $9.76 billion, every additional $100 million of tariff cost would reduce gross margin by about 1 percentage point[18]. If the second-quarter non-GAAP gross margin is at least 65.5% and the company does not raise its tariff cost estimate, the threat to margins would be limited[6].

What to Watch Next

• PFA and the heart-rhythm business: EPT growth was 30% on $2.218 billion of revenue including 14 weeks[4]; growth of at least 20% on a 13-week basis would confirm the current reading and anything lower would falsify it. CAS grew 88% including 14 weeks[5]; growth below 50% would falsify it. The Cardiovascular segment margin was 26.3% against 25.2% a year earlier[7]; falling below the prior-year level would falsify it.
• Post-separation underlying growth: second-quarter guidance is about 6% organic growth and EPS of $1.32 to $1.34[6]; organic growth below 5.5% or EPS below $1.32 would falsify it. Full-year guidance stands at EPS of $5.94 to $6.00 and 7.25% to 7.75% organic growth[5]; a reset EPS range with a low end below $5.94 would falsify it.
• Margins and cash conversion: non-GAAP gross and operating margins were 65.2% and 23.7%[6]; a gross margin back above 65.5% would confirm improvement, while a gross margin below 65.0% or an operating margin below 23.0% would falsify it. The Medical Surgical margin was 21.3% against 23.7% a year earlier[7]; a further decline would falsify recovery. First-quarter free cash flow was $1.290 billion against $584 million[15]; first-half free cash flow below the prior year would falsify the cash-conversion improvement.

Conclusion

Medtronic's business is driven by procedure volume, new-product penetration and product mix, and the most important relationship now is whether PFA-led growth can turn into margin expansion in a normal quarter. In the first quarter of fiscal 2027, revenue was $9.756 billion with 13.7% organic growth and free cash flow was $1.290 billion, yet non-GAAP gross and operating margins rose by only 10 basis points[5]; net debt was about $19.3 billion at the end of July, and the MiniMed separation completed in October lowers both the revenue base and the share count[16]. The second quarter is the first without the extra week and MiniMed, and it will test these relationships on a single clean basis for the first time.

Independent analysis published after the first-quarter results is scarce: only Gian Estrada of TIKR published a substantive article, on September 2, while the rest of the coverage consisted of daily stock reports, reprinted press releases and exchange-offer notices. Estrada judged the first-quarter beat to be broad-based but cautioned that the extra week added about $570 million, or 6.7 percentage points of growth, and highlighted CAS growth of 88% worldwide and 139% in the United States; he read the $700 million Cornerstone Robotics investment announced the same day as a bid for access to markets outside the United States rather than a hedge against Hugo, and noted that Hugo is on pace to pass 50,000 completed procedures by fiscal year-end[20]. His article bears directly on the first and second debates: it likewise treats the extra week as the key to reading the growth rate, but its reading of Cornerstone leans toward strategic expansion and does not address whether that spending is depressing the Medical Surgical margin. A single outside view cannot represent the market's overall interpretation.

The combination that would materially strengthen the current understanding is second-quarter EPT growth of at least 20% and CAS growth above 60%, organic growth of about 6% with EPS in the $1.32 to $1.34 range, a non-GAAP gross margin back above 65.5% and a Medical Surgical margin above 22%, and a reset full-year EPS range whose low end is at least $5.94[6]. Conversely, if PFA growth slows markedly and the Cardiovascular margin falls below the prior-year level, while the post-separation EPS range is cut and the non-GAAP operating margin drops below 23.0%, the first quarter's strength would have come mainly from the extra week and one-off factors, and both the growth and the profit quality of post-separation Medtronic would need to be reassessed.

Sources

[1] MDT 10-K filed 2026-06-18 sales and distribution · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[2] Drillr earnings calendar 2026-11-10 MDT Q2 FY27 · 2026-11-10 · Drillr 财报日历(汇总分析师预期) · https://gateway.drillr.ai/mcp/private

[3] MDT 8-K filed 2026-10-19 MiniMed separation completed · 2026-10-19 · 8-K · https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001613103&type=8-K&dateb=&owner=include&count=40

[4] MDT 10-Q filed 2026-09-03 net sales by division · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[5] MDT 8-K filed 2026-09-01 Q1 FY27 results · 2026-09-01 · 8-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026059697/

[6] MDT Q1 FY27 earnings call 2026-09-01 · 2026-09-01 · earnings-call · https://quartr.com/events/medtronic-mdt-q1-2027_3e2PNIkN

[7] MDT 10-Q filed 2026-09-03 segment operating profit · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[8] MDT 10-K filed 2026-06-18 · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[9] MDT 10-Q filed 2026-09-03 53-week year and acquisitions · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[10] MDT 10-K filed 2026-06-18 net sales by division · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[11] MDT 10-K filed 2026-06-18 MiniMed separation · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[12] MDT 10-K filed 2026-06-18 segment operating profit · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[13] MDT 10-K filed 2026-06-18 cash flows · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[14] MDT 10-K filed 2026-06-18 cost of products sold and tariffs · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[15] MDT 10-Q filed 2026-09-03 free cash flow · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[16] MDT 10-Q filed 2026-09-03 balance sheet · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[17] MDT 10-Q filed 2026-09-03 Cardiovascular commentary · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[18] MDT 10-Q filed 2026-09-03 cost of products sold · 2026-09-03 · 10-Q · https://www.sec.gov/Archives/edgar/data/1613103/000162828026060473/

[19] MDT 10-K filed 2026-06-18 Cardiovascular commentary · 2026-06-18 · 10-K · https://www.sec.gov/Archives/edgar/data/1613103/000162828026044354/

[20] TIKR 2026-09-02 Medtronic Q1 and Cornerstone · 2026-09-02 · TIKR · https://www.tikr.com/blog/medtronics-q1-earnings-blew-past-estimates-then-it-made-a-700-million-bet-against-its-own-robot